News Acceleron axes clinical development of muscular dystrophy dr... Acceleron has axed clinical development of its ACE-083 in the inherited muscle-wasting disease muscular dystrophy, after the drug fell short against efficacy measures in a phase 2 trial.
Digital Axtria Ignite 2025: Madhavi Ramakrishna on leadership, cultu... GSK's Madhavi Ramakrishna was the recipient of one of the annual Axtria Ignite Leadership Awards presented at the invite-only summit.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
